On May 16, 2023, the US Court of Appeals for the Second Circuit affirmed the Southern District of New York’s order dismissing an action brought by investors of AstraZeneca PLC (AstraZeneca) attempting to hold the company...more
6/19/2023
/ AstraZeneca ,
Class Action ,
Clinical Trials ,
Dismissals ,
Material Misstatements ,
Pharmaceutical Industry ,
Popular ,
Rule 10b-5 ,
Securities Exchange Act ,
Securities Litigation ,
Shareholder Litigation ,
Vaccinations
On September 27, 2022, U.S. District Judge Kevin McNulty of the District of New Jersey dismissed a consolidated derivative action allegedly brought on behalf of Cognizant Technology Solutions Corporation against certain...more
11/3/2022
/ Administrative Hearings ,
Caremark claim ,
Class Action ,
Compliance ,
Constitutional Challenges ,
Cooperation ,
Department of Justice (DOJ) ,
Derivative Suit ,
Foreign Corrupt Practices Act (FCPA) ,
Indictments ,
Non-Fungible Tokens (NFTs) ,
Popular ,
Securities and Exchange Commission (SEC) ,
Securities Exchange Act ,
Securities Litigation ,
Shareholder Litigation ,
Shareholders
Delaware Federal Court Dismisses Shareholder Derivative Suit Concerning Lack of Board Diversity; California Federal Court Dismisses Shareholder Class Action Against Sorrento Therapeutics Regarding COVID-19 Treatment; Delaware...more
12/23/2021
/ Board of Directors ,
Cannabis-Related Businesses (CRBs) ,
Class Action ,
Coronavirus/COVID-19 ,
Derivative Suit ,
Discovery ,
Discovery Violations ,
Dismissals ,
Diversity ,
False Statements ,
Investment Fraud ,
Investors ,
Misleading Statements ,
Misrepresentation ,
Pharmaceutical Industry ,
Popular ,
Putative Class Actions ,
Rule 10b-5 ,
Scienter ,
Securities Exchange Act of 1934 ,
Securities Violations ,
Shareholder Litigation ,
Shareholders